Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends

Core Insights - The FDA has announced that the supply of unapproved domperidone is expected to be exhausted by early 2025, highlighting the urgent need for alternative treatments for gastroparesis [2][4] - GIMOTI, a nasal spray formulation of metoclopramide, is the only FDA-approved treatment for acute and recurrent diabetic gastroparesis, positioning it as a critical option for patients [1][6] - Real-world evidence indicates that GIMOTI significantly reduces emergency room visits by 60% and hospitalizations by 68% compared to oral metoclopramide, demonstrating its clinical effectiveness [4][5] Company Overview - Evoke Pharma, Inc. is a specialty pharmaceutical company focused on developing treatments for gastrointestinal diseases, with GIMOTI being its primary product [5][6] - The company emphasizes its commitment to providing innovative solutions for patients suffering from gastroparesis, particularly as alternative treatments become less accessible [5][6] Market Context - Gastroparesis is a debilitating condition that leads to delayed stomach emptying, causing severe symptoms and complications, which makes effective treatment options essential [3][6] - The discontinuation of domperidone supply underscores the need for safe and effective therapies like GIMOTI, which bypasses the gastrointestinal tract and addresses the core issues of delayed gastric emptying [2][4]